| DESCRIPTION | - DESCOMBE J.J. et al., "Pharmacokinetic study of rifaximin after oral administration in healthy volunteers", Int J Clin Pharmacol Res, (19940000), vol. 14, no. 2, pages 51 - 56 | - |
| DESCRIPTION | - G. C. VISCOMI et al., CrystEngComm, (20080400), vol. 10, pages 1074 - 1081 | - |
| DESCRIPTION | - G. M. WALL, Pharm Manuf., (19860000), vol. 3, page 33 | - |
| DESCRIPTION | - J. K. HALEBLIAN, J. Pharm. Sci., (19750000), vol. 64, page 1269 | - |
| DESCRIPTION | - J. K. HALEBLIANW. MCCRONE, J Pharm. Sci., (19690000), vol. 58, page 911 | - |
| EXAMINATION | - Anonymous, "Xifaxan (rifaximin) FDA Approval History - Drugs.com", (20150527), URL: https://www.drugs.com/history/xifaxan.html, (20230113), XP093013686 | - |
| EXAMINATION | - "Rivaximin Treatment is Beneficial for Mild Hepatic Encephalopathy", Nathan M. Bass et al., Presented at the "LIVER MEETING", OCTOBER 29 - NOVEMBER 2, 2004, Boston, Massachusetts | - |
| EXAMINATION | - MARSHA Y MORGAN ET AL, "The treatment of hepatic encephalopathy", METABOLIC BRAIN DISEASE, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, (20070906), vol. 22, no. 3-4, doi:10.1007/S11011-007-9060-7, ISSN 1573-7365, pages 389 - 405, XP019554851 | |
| EXAMINATION | - RUIZ J. ET AL, "Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, GB, (20080305), vol. 61, no. 5, doi:10.1093/jac/dkn078, ISSN 0305-7453, pages 1016 - 1019, XP093013075 | |
| EXAMINATION | - FARRELL DAVID J., "Rifaximin in the Treatment of Irritable Bowel Syndrome : Is There a High Risk for Development of Antimicrobial Resistance?", JOURNAL OF CLINICAL GASTROENTEROLOGY., US, (20130301), vol. 47, no. 3, doi:10.1097/MCG.0b013e31827559a3, ISSN 0192-0790, pages 205 - 211, XP093013279 | |
| EXAMINATION | - ALS-NIELSEN BODIL ET AL, "Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials", BMJ, GB, (20040501), vol. 328, no. 7447, doi:10.1136/bmj.38048.506134.EE, ISSN 0959-8138, page 1046, XP093057197 | |
| EXAMINATION | - LAWRENCE KENNETH R ET AL, "Rifaximin for the treatment of hepatic encephalopathy", PHARMACOTHERAPY, WILEY-BLACKWELL, US, vol. 28, no. 8, doi:10.1592/PHCO.28.8.1019, ISSN 0277-0008, (20080801), pages 1019 - 1032, (20120106), XP008148564 | |
| OPPOSITION | - Anonymous, "22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results Table of Contents", FDA, (20170101), XP093303598 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00364689 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial", Clinical Trial Study NCT00364689, (20060815), Clinical Trial Study NCT00364689, URL: https://clinicaltrials.gov/ct2/history/NCT00364689?V_1=View#StudyPageTop, (20210201), XP055770763 | - |
| OPPOSITION | - Anonymous, "ICH Topic E 8 General Considerations for Clinical Trials - Step 4, Consensus guideline", EMA; NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95), (19970717), XP093235687 | - |
| OPPOSITION | - Anonymous, " NORMIX - Rifaximin - Granules for oral suspension 2 g/100 ml - 60 ml bottle", ALFA Farmaceu ci S.p.A., (19850101), XP093303575 | - |
| OPPOSITION | - Ausmus Ashley, Ludwig Shannon, "Overt Hepatic Encephalopathy: Pharmacotherapy Review ", medicine2.missouri.edu, (20150105), XP093303594 | - |
| OPPOSITION | - Bass Nathan M, Nm, Gardner Jd, Kamm Ar , "Rifaximin is beneficial for the treatment of hepatic encephalopathy. Presented at the 53rd Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA. (2004, October 29-November 2) ", (20041029), (20231219), XP093113755 | - |
| OPPOSITION | - Blei, A.T. ; Cordoba, J. ; The Practice Parameters Committee of the American College of ; Gastroenterology, "Hepatic encephalopathy", AMERICAN JOURNAL OF GASTROENTEROLOGY, ELSEVIER SCIENCE INC., US, US , (20010701), vol. 96, no. 7, ISSN 0002-9270, pages 1968 - 1976, XP027391873 | - |
| OPPOSITION | - D10a - Evidence of publication date of 31 May for D10 | - |
| OPPOSITION | - D10b - Evidence of publication date of 2009 for D10 | - |
| OPPOSITION | - D3 - Applicant’s 11 November 2022 response (EP 19207534.9) | - |
| OPPOSITION | - D4 - Applicant’s 19 May 2023 response (EP 19207534.9) | - |
| OPPOSITION | - D50 - EPO Examining Division Office Action on EP19207534.9, dated 19 January 2023 | - |
| OPPOSITION | - D52 - Preliminary Opinion of the Boards of Appeal on EP 2350096, dated 25 October 2024 | - |
| OPPOSITION | - D54a - Publication details of D54 | - |
| OPPOSITION | - D56 - English translation | - |
| OPPOSITION | - D5a - Evidence of publication date of 23 September 2009 for D5 | - |
| OPPOSITION | - D5a - Index of Hepatology, 2009, 50, Suppl. 4 | - |
| OPPOSITION | - D6 - Applicant’s 11 October 2023 response (EP 19207534.9) | - |
| OPPOSITION | - D7 - Opposition Division’s Decision dated 4 November 2022 (EP 09 818 544.0) | - |
| OPPOSITION | - D8 - Orange Book listing for rifaximin | - |
| OPPOSITION | - D9 - Normix syrup - ‘Annex 1’ referred to in Applicant’s 19 May 2023 response | - |
| OPPOSITION | - DE LEO C; EFTIMIADI C; SCHITO G C, "RAPID DISAPPEARANCE FROM THE INTESTINAL TRACT OF BACTERIA RESISTANT TO RIFAXIMIN", Drugs under Experimental and Clinical Research, Bioscience Ediprint Inc., CH, CH , (19860101), vol. 12, no. 12, ISSN 0378-6501, pages 979 - 981, XP009182467 | - |
| OPPOSITION | - D. Festi, Vestito A., Mazzella G., Roda E., Colecchia A., "Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy", Digestion, (20060201), vol. 73, no. suppl 1, pages 94 - 101, XP055771240 | - |
| OPPOSITION | - EFTIMIADI C; DELEO C; SCHITO G C, "TREATMENT OF HEPATIC ENCEPHALOPATHY WITH L-105 A NEW NON-ABSORBABLE RIFAMYCIN", Drugs under Experimental and Clinical Research, Bioscience Ediprint Inc., CH, CH , (19840101), vol. 10, no. 10, ISSN 0378-6501, pages 691 - 696, XP009182468 | - |
| OPPOSITION | - Ernst Mutschler Et Al.,, "10.2 Klinische Prüfung", Mutschler Arzneimittelwirkungen Lehrbuch der Pharmakologie und Toxikologie, Stuttgart , Wissenschaftliche Verlagsgesellschaft mbH , (20010101), pages 2pp, 123 - 124, XP055616830 | - |
| OPPOSITION | - Fred Poordad, Nathan Bass, Arun J. Sanya, Muhammad Y. Sheikh, Kevin D. Mullen, Samuel Sigal, Todd Frederick, Robert S. Brown, Shobha Joshi, Kunal Merchant, Shirley Huang, Audrey L. Shaw, Enoch Bortey William P. Forbes, "THE PROTECTIVE EFFECT OF RIFAXIMIN (1100 MG DAILY) FROM. HEPATIC ENCEPHALOPATHY OBSERVED IN A DOUBLE-BUND PLACEBO CONTROLLED STUDY ISSUBSTANTIATED AND DURABLE OVER THE LONG", Hepatology, (20091001), vol. 50, no. Suppl 4, pages 448A - 449A, XP055770758 | - |
| OPPOSITION | - Hiroki Ohge ; Julie K. Furne ; John Springfield ; David A. Rothenberger ; Robert D. Madoff ; Michael D. Levitt, "Association Between Fecal Hydrogen Sulfide Production and Pouchitis", Diseases of the Colon & Rectum, Lippincott Williams & Wilkins, US, US , (20050301), vol. 48, no. 3, ISSN 1530-0358, pages 469 - 475, XP019368787 | - |
| OPPOSITION | - Janet Yang ; Hyo-Rang Lee ; Kimberly Low ; Soumya Chatterjee ; Mark Pimentel, "Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS", Digestive Diseases and Sciences, Kluwer Academic Publishers-Plenum Publishers, Ne, Ne , (20070523), vol. 53, no. 1, ISSN 1573-2568, pages 169 - 174, XP019550554 | - |
| OPPOSITION | - Jiang Z D, Et Al, "Rifaximin: In vitro and in vivo Antibacterial Activity - A Review", Chemotherapy, (20050101), vol. 51, pages 67 - 72, XP055816074 | - |
| OPPOSITION | - Lichtenstein G R, "Rifaximin: Recent advances in gastroenterology and hepatology", Gastroenterology & Hepatology, Millennium Medical Publishing, US, US , (20070601), vol. 3, no. 6, ISSN 1554-7914, pages 474 - 483, XP009155230 | - |
| OPPOSITION | - Loguercio Carmelina, Et Al, "Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study", Minerva Gastroenterologica e Dietologica, (20040301), pages 53 - 62, Minerva Gastroenterologica e Dietologica, (20210621), XP055816069 | - |
| OPPOSITION | - Mantry Parvez S, Swapnil Munsaf, "ANALYSIS OF THE EFFECT OF RIFAXIMIN PLUS LACTU LOSE ON HOSPITALIZATIONS IN PATIENTS WITH END STAGE LIVER DISEASE", Hepatology, AASLD ABSTRACTS, (20081001), vol. 48, no. 4, pages 1082A - 1082A, XP093235694 | - |
| OPPOSITION | - Rachel Tavares De Melo, Lisa Charneski And Olga Hilas, "Rifaximin for the Treatment of Hepatic Encephalopathy", Am J Health-Syst Pharm, (20080501), vol. 65, pages 818 - 822, XP055767702 | - |
| OPPOSITION | - Salix Pharmaceuticals, Inc, "Xifaxan Prescribing Information", (20080301), pages 1 - 2, XP008139843 | - |
| OPPOSITION | - Salix Pharmaceuticals, "NCT00298038 A 6-Month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy - Tabular View - ClinicalTrials.gov", ClinicalTrials.org, NLM, pages 1 - 4, ClinicalTrials.org, URL: https://web.archive.org/web/20080525053506/http://clinicaltrials.gov/ct2/show/record/NCT00298038, XP093238453 | - |
| OPPOSITION | - Als-Nielsen Bodil, Gluud Lise Lotte, Gluud Christian, "Nonabsorbable disaccharides for hepatic encephalopathy", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, Chichester, West Sussex, England : Wiley, GB, GB , (20040419), no. 2, doi:10.1002/14651858.CD003044.pub2, ISSN 1469-493X, page CD003044, XP009562903 | |
| OPPOSITION | - Wong, Florence; Gines, Pere; Nevens, Frederik; Van Vlierberghe, Hans; Gerbes, Alexander L.; Zarski, Jean Pierre H.; Koch, Alvaro; Badalamenti, Salvatore; Minini, Pascal; Watson, Hugh R., "304: DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SATAVAPTAN IN THE MANAGEMENT OF RECURRENT ASCITES: THE SPARE-1 STUDY 304", Hepatology, John Wiley & Sons, Inc., US, US , (20091001), vol. 50, no. S4, doi:10.1002/hep.23301, ISSN 0270-9139, page 448A, XP009558828 | |
| OPPOSITION | - Sanaka, Madhusudhan R.; Ong, Janus P.; Mullen, Kevin D., "Challenges of Designing Hepatic Encephalopathy Treatment Trials", Hepatology, (20030800), vol. 38, no. 2, doi:10.1002/hep.510380231, pages 527 - 529, XP071559672 | |
| OPPOSITION | - Duffy M., Oʼmahony L., Coffey J. C., Collins J. K., Shanahan F., Redmond H. P., Kirwan W. O., "Sulfate-Reducing Bacteria Colonize Pouches Formed for Ulcerative Colitis but Not for Familial Adenomatous Polyposis", DISEASES OF THE COLON AND RECTUM., J.B. LIPPINCOT CO., PHILADELPHIA., US, US , (20020301), vol. 45, no. 3, doi:10.1007/s10350-004-6187-z, ISSN 0012-3706, pages 384 - 388, XP009562398 | |
| OPPOSITION | - LEEVY CARROLL B ,PHILLIPS JAMES A, "Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.", DIGESTIVE DISEASES AND SCIENCES., Springer New York LLC, US, US , (20070301), vol. 52, no. 3, doi:10.1007/S10620-006-9442-4, ISSN 0163-2116, pages 737 - 741, XP002669396 | |
| OPPOSITION | - Marsha Y. Morgan ; A. Blei ; K. Grüngreiff ; R. Jalan ; G. Kircheis ; G. Marchesini ; O. Riggio ; Karin Weissenborn, "The treatment of hepatic encephalopathy", Metabolic Brain Disease, Kluwer Academic Publishers-Plenum Publishers, Ne, Ne , (20070906), vol. 22, no. 3-4, doi:10.1007/s11011-007-9060-7, ISSN 1573-7365, pages 389 - 405, XP019554851 | |
| OPPOSITION | - Guy Neff, Woodie Zachry Iii, "Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin", PHARMACOECONOMICS, ADIS INTERNATIONAL, AUCKLAND, NZ, NZ , (20180701), vol. 36, no. 7, doi:10.1007/s40273-018-0641-6, ISSN 1170-7690, pages 809 - 822, XP055662447 | |
| OPPOSITION | - Mullen Kevin D., Sanyal Arun J., Bass Nathan M., Poordad Fred F., Sheikh Muhammad Y., Frederick R. Todd, Bortey Enoch, Forbes William P., "Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy", Clinical Gastroenterology and Hepatology, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20140801), vol. 12, no. 8, doi:10.1016/j.cgh.2013.12.021, ISSN 1542-3565, pages 1390 - 1397.e2, XP093303578 | |
| OPPOSITION | - Sama, C. Morselli-Labate, A.M. Pianta, P. Lambertini, L. Berardi, S. Martini, G., "Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study", CURRENT THERAPEUTIC RESEARCH, EXCERPTA MEDICA, TRENTON, NJ, US, US , (20040901), vol. 65, no. 5, doi:10.1016/j.curtheres.2004.10.002, ISSN 0011-393X, pages 413 - 422, XP004687713 | |
| OPPOSITION | - Riggio, O. ; Masini, A. ; Efrati, C. ; Nicolao, F. ; Angeloni, S. ; Salvatori, F.M. ; Bezzi, M. ; Attili, A.F. ; Merli, M., "Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study", Journal of Hepatology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20050501), vol. 42, no. 5, doi:10.1016/j.jhep.2004.12.028, ISSN 0168-8278, pages 674 - 679, XP025293043 | |
| OPPOSITION | - Munoz Santiago J, "Hepatic encephalopathy", MEDICAL CLINICS OF NORTH AMERICA., W.B. Saunders Co., US, US , (20080701), vol. 92, no. 4, doi:10.1016/j.mcna.2008.03.009, ISSN 0025-7125, pages 795 - 812, XP008116796 | |
| OPPOSITION | - Neff, G.W. Kemmer, N. Zacharias, V.C. Kaiser, T. Duncan, C. McHenry, R. Jonas, M. Novick, D. Williamson, C. Hess, K. Thomas, M. Buell, J., "Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy", TRANSPLANTATION PROCEEDINGS, Elsevier Inc., ORLANDO, FL; US, ORLANDO, FL; US , (20061215), vol. 38, no. 10, doi:10.1016/j.transproceed.2006.10.107, ISSN 0041-1345, pages 3552 - 3555, XP005804096 | |
| OPPOSITION | - Neff, G. ; Leevy, C.B. ; Frederick, T. ; Merchant, K. ; Huang, S. ; Shaw, A.L. ; Forbes, W.P., "66 Rifaximin Reduces the Risk of Hospitalizations in Patients with Previous Episodes of Hepatic Encephalopathy: Results from a Phase 3 Placebo-Controlled Trial", Gastroenterology, Elsevier Inc., US, US , (20090501), vol. 136, no. 5, doi:10.1016/S0016-5085(09)60056-1, ISSN 0016-5085, pages A - 12, XP026110603 | |
| OPPOSITION | - Mas Antoni, Rodés Juan, Sunyer Lourdes, Rodrigo Luı́s, Planas Ramon, Vargas Victor, Castells Lluı́s, Rodrı́guez-Martı́nez Dolores, Fernández-Rodrı́guez Conrado, Coll Ignasi, Pardo Albert, "Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial", Journal of Hepatology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20030101), vol. 38, no. 1, doi:10.1016/S0168-8278(02)00350-1, ISSN 0168-8278, pages 51 - 58, XP093303582 | |
| OPPOSITION | - Arrowsmith John, "Phase III and submission failures: 2007-2010", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , (20110201), vol. 10, no. 2, doi:10.1038/nrd3375, ISSN 1474-1776, pages 87 - 87, XP038240425 | |
| OPPOSITION | - Ferenci Peter; Lockwood Alan; Mullen Kevin; Tarter Ralph; Weissenborn Karin; Blei Andres T., "Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998", Hepatology, John Wiley & Sons, Inc., US, US , (20021030), vol. 35, no. 3, doi:10.1053/jhep.2002.31250, ISSN 0270-9139, pages 716 - 721, XP029576907 | |
| OPPOSITION | - Bass, Nathan M., "Emerging therapies for the management of hepatic encephalopathy", Seminars in liver disease, Thieme Medical Publishers, US, US , (20070801), vol. 27, no. suppl. 2, doi:10.1055/s-2007-984575, ISSN 0272-8087, pages 18 - 25, XP008148563 | |
| OPPOSITION | - Nathan M. Bass, Kevin D. Mullen, Et Al., "Rifaximin Treatment in Hepatic Encephalopathy", The New England Journal of Medicine, (20100325), vol. 362, no. 12, doi:10.1056/NEJMoa0907893, pages 1071 - 1081, XP055616660 | |
| OPPOSITION | - Baysarowich Jennifer, Koteva Kalinka, Hughes Donald W., Ejim Linda, Griffiths Emma, Zhang Kun, Junop Murray, Wright Gerard D., "Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (20080325), vol. 105, no. 12, doi:10.1073/pnas.0711939105, ISSN 0027-8424, pages 4886 - 4891, XP093235680 | |
| OPPOSITION | - Ruiz J., Mensa L., Pons M. J., Vila J., Gascon J., "Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability", Journal of antimicrobial chemotherapy, OXFORD UNIVERSITY PRESS, GB, GB , (20080305), vol. 61, no. 5, doi:10.1093/jac/dkn078, ISSN 0305-7453, pages 1016 - 1019, XP093013075 | |
| OPPOSITION | - R Williams, James Of, Warnes Tw, Morgan My., "Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.", Eur J Gastroenterol Hepatol, (20000201), vol. 12, no. 2, doi:10.1097/00042737-200012020-00012, pages 203 - 208, XP055408536 | |
| OPPOSITION | - Farrell David J., "Rifaximin in the Treatment of Irritable Bowel Syndrome : Is There a High Risk for Development of Antimicrobial Resistance?", JOURNAL OF CLINICAL GASTROENTEROLOGY., RAVEN PRESS LTD., NEW YORK, NY., US, US , (20130301), vol. 47, no. 3, doi:10.1097/MCG.0b013e31827559a3, ISSN 0192-0790, pages 205 - 211, XP093013279 | |
| OPPOSITION | - Rothstein David M., "Rifamycins, Alone and in Combination", Cold Spring Harbor perspectives in medicine, Cold Spring Harbor, NY : Cold Spring Harbor Laboratory Press, US, US , (20160701), vol. 6, no. 7, doi:10.1101/cshperspect.a027011, ISSN 2157-1422, page a027011, XP093303590 | |
| OPPOSITION | - Falck-Ytter Yngve, Kunz Regina, Guyatt Gordon H., Schünemann Holger J., "How Strong Is the Evidence?", AMERICAN JOURNAL OF GASTROENTEROLOGY, ELSEVIER SCIENCE INC., US, US , (20080601), vol. 103, no. 6, doi:10.1111/j.1572-0241.2008.01853.x, ISSN 0002-9270, pages 1334 - 1338, XP009562394 | |
| OPPOSITION | - R WILLIAMS, "Review article: bacterial flora and pathogenesis in hepatic encephalopathy", Alimentary Pharmacology & Therapeutics, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE., GB, GB , (20070123), vol. 25, doi:10.1111/j.1746-6342.2006.03217.x, ISSN 0269-2813, pages 17 - 22, XP071540655 | |
| OPPOSITION | - BASS N M, "Review article: the current pharmacological therapies for hepatic encephalopathy.", Alimentary Pharmacology & Therapeutics, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE., GB, GB , (20070201), vol. 25, no. SUPPL 1, doi:10.1111/J.1746-6342.2006.03218.X, ISSN 0269-2813, pages 23 - 31, XP002669397 | |
| OPPOSITION | - Williams D. L., Spring L., Collins L., Miller L. P., Heifets L. B., Gangadharam P. R. J., Gillis T. P., "Contribution of rpoB Mutations to Development of Rifamycin Cross-Resistance in Mycobacterium tuberculosis", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (19980701), vol. 42, no. 7, doi:10.1128/AAC.42.7.1853, ISSN 0066-4804, pages 1853 - 1857, XP093303587 | |
| OPPOSITION | - Als-Nielsen Bodil, Gluud Lise L, Gluud Christian, "Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials", BMJ, BMJ, (20040501), vol. 328, no. 7447, doi:10.1136/bmj.38048.506134.EE, ISSN 0959-8138, page 1046, XP093057197 | |
| OPPOSITION | - Zeneroli, Maria Luisa; Avallone, Rossella; Corsi, Lorenzo; Venturini, Ivo; Baraldi, Claudia; Baraldi, Mario, "Management of Hepatic Encephalopathy: Role of Rifaximin", Chemotherapy, S. Karger AG, CH, CH , (20050401), vol. 51, no. suppl. 1, doi:10.1159/000081994, ISSN 0009-3157, pages 90 - 95, XP008148562 | |
| OPPOSITION | - PELOSINI I, SCARPIGNATO C, "RIFAXIMIN, A PECULIAR RIFAMYCIN DERIVATIVE: ESTABLISHED AND POTENTIAL CLINICAL USE OUTSIDE THE GASTROINTESTINAL TRACT", Chemotherapy, S. Karger AG, CH, CH , (20050401), vol. 51, no. SUPPL. 1, doi:10.1159/000081999, ISSN 0009-3157, pages 122 - 130, XP008074543 | |
| OPPOSITION | - Steven L. Flamm, "Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence", Therapeutic advances in gastroenterology, London : Sage, UK, UK , (20110501), vol. 4, no. 3, doi:10.1177/1756283X11401774, ISSN 1756-283X, pages 199 - 206, XP055662444 | |
| OPPOSITION | - A. Puxeddu, M. Quartini, A. Massimetti, "Rifaximin in the treatment of chronic hepatic encephalopathy", Current Medical Research and Opinion, (19950101), vol. 13, doi:10.1185/03007999509111552, pages 274 - 281, XP055733786 | |
| OPPOSITION | - Miglio F; Valpiani D; Rossellini S R; Ferrieri A, "Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial", Current Medical Research and Opinion, HANTS, GB, GB , (19970101), vol. 13, no. 10, doi:10.1185/03007999709113333, ISSN 0300-7995, pages 593 - 601, XP009175422 | |
| OPPOSITION | - Shen Bo, Remzi Feza H, Lopez A Rocio, Queener Elaine, "Rifaximin for maintenance therapy in antibiotic-dependent pouchitis", BMC GASTROENTEROLOGY, BIOMED CENTRAL LTD., LONDON, GB, GB , (20080623), vol. 8, no. 1, doi:10.1186/1471-230X-8-26, ISSN 1471-230X, XP093113628 | |
| OPPOSITION | - Gerard L, Garey K W, DuPont H L, "Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointerstinal infections", EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, FUTURE DRUGS, LONDON, GB, GB , (20050401), vol. 3, no. 2, doi:10.1586/14787210.3.2.201, ISSN 1478-7210, pages 201 - 211, XP008119006 | |
| OPPOSITION | - Lawrence, Kenneth R.; Klee, Jacqueline A., "Rifaximin for the treatment of hepatic encephalopathy", Pharmacotherapy, Wiley-Blackwell, US, US , (20080801), vol. 28, no. 8, doi:10.1592/phco.28.8.1019, ISSN 0277-0008, pages 1019 - 1032, XP008148564 | |
| OPPOSITION | - Neff Guy, "Factors Affecting Compliance and Persistence with Treatment for Hepatic Encephalopathy", Pharmacotherapy, Wiley-Blackwell, US, US , (20100501), vol. 30, no. 5P2, doi:10.1592/phco.30.pt2.22S, ISSN 0277-0008, XP093303584 | |
| OPPOSITION | - Neff Guy, "Pharmacoeconomics of Hepatic Encephalopathy", Pharmacotherapy, Wiley-Blackwell, US, US , (20100501), vol. 30, no. 5P2, doi:10.1592/phco.30.pt2.28S, ISSN 0277-0008, XP093303593 | |
| OPPOSITION | - PAIK ET AL., "Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study", Yonsei Medical Journal, Yonsei University, KI, KI , (20050630), vol. 46, no. 3, doi:10.3349/ymj.2005.46.3.399, ISSN 0513-5796, pages 399 - 407, XP008139597 | |
| OPPOSITION | - Colecchia Antonio, Vestito Amanda, Pasqui Francesca, Mazzella Giuseppe, Roda Enrico, Pistoia Francesca, Brandimarte Giovanni, Festi Davide, Mazzella Giu- Seppe, , , "Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease", World Journal of Gastroenterology, WJG Press, CN, CN , (20070101), vol. 13, no. 2, doi:10.3748/wjg.v13.i2.264, ISSN 1007-9327, page 264, XP093235690 | |
| OPPOSITION | - Adachi Javier A, Dupont Herbert L, "Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders", Clinical Infectious Diseases, Volume 42(4):541-547, doi:https://doi.org/10.1086/502714, (20060215), pages 541 - 547, Clinical Infectious Diseases, Volume 42(4):541-547, URL: https://watermark.silverchair.com/42-4-541.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA14wggNaBgkqhkiG9w0BBwagggNLMIIDRwIBADCCA0AGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMZFpkIC8jN1d3MmbCAgEQgIIDEc4stA_8P77SubxorTjetieJawicptyE_329NMZ84f2pOYqv5_DsEJuL0H3ApQFX_T19rk49GlIcHYHmr7Pxn7BjeAJCH70ggjVDqVqeDl0Juypirh_oc4ybRADIkITnBMGjWAJkZc1O4hxte2hSUypxajpN--oQoh8-Zi4E55Yb2NDoUaMKC_pqh7T1lum0aDl9mdzgGYmJOxrYjjj5Ea36YxBdORwkhm-bL5aBf2P10IzbXcs0m2REtLt1SskhmdvbFhHYuFX5cKBkH0swI0WTwWHkZBmDFjW4xljzFAFTmSCfG07QxrNuwQvylHwYuReobQcQNLEgEAyGu7w1E4qaOFJD1GqN2NEtDmzPV9WOn2kuIlWhwaQE8nyIZZJmO9bxv2sudPObGw5tY9z3KP5HnHMPiaFJfDrSbxOVNkgV6OQ7lIdBRUHqZaFEyWr8ffCdmkym7BSKIHUYZX1ZUzacrDQnAYWtY4IEJrHggLRzxMinwwNZve6v-huQD3h0YiqvZnXR8GFB49dBZTApwqiYk5kAwkWkAIl-E-GFL9l_0yzC4i1PDVf90P0oD3a2vdGjV7mHZz1zvuugKeJE3b625FhWCRtGENLbCeeAVCDb2HPY9XCsRj66rCBff3uycZMOPeaFkcFbBDPnnlwPGVFB1ZXhBhYR9IFWFjGpvdNK28GLnOaP-N7-AK6z6Dg7ZAeRf_TfAoz7LX4GgivIbKCgJq1lWJ9BLByx5uR8dKSuu-P2BeihLYoDIhafiMvGqVAsGP4Qytn7PX9LxFd63K6, (20240220), XP093133367 | |
| SEARCH | - SALIX PHARMACEUTICALS ET AL, "Xifaxan Prescribing Information", (20080301), pages 1 - 2, 20080301, URL: http://www.salix.com/assets/pdf/prescribe_into/xifaxanpi.pdf, (20110405), XP008139843 [A] 1-9 * the whole document * | - |
| SEARCH | - LEEVY CARROLL B ET AL, "Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.", DIGESTIVE DISEASES AND SCIENCES MAR 2007 LNKD- PUBMED:17245628, (200703), vol. 52, no. 3, ISSN 0163-2116, pages 737 - 741, XP002669396 [A] 1-9 * the whole document * * page 739 - page 741 * | |
| SEARCH | - GUY NEFF ET AL, "Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin", PHARMACOECONOMICS, NZ, (20180412), vol. 36, no. 7, doi:10.1007/s40273-018-0641-6, ISSN 1170-7690, pages 809 - 822, XP055662447 [T] * the whole document * | |
| SEARCH | - BASS ET AL, "Emerging therapies for the management of hepatic encephalopathy", SEMINARS IN LIVER DISEASE, THIEME MEDICAL PUBLISHERS, US, (20070801), vol. 27, no. suppl. 2, doi:10.1055/S-2007-984575, ISSN 0272-8087, pages 18 - 25, XP008148563 [A] 1-9 * paragraph [02nd] * * page 23, column left, paragraph 1st * * the whole document * | |
| SEARCH | - NATHAN M. BASS ET AL, "Rifaximin Treatment in Hepatic Encephalopathy", THE NEW ENGLAND JOURNAL OF MEDICINE, (20100325), vol. 362, no. 12, doi:10.1056/NEJMoa0907893, pages 1071 - 1081, XP055616660 [T] * the whole document * | |
| SEARCH | - R WILLIAMS ET AL, "Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.", EUR J GASTROENTEROL HEPATOL, (20000201), vol. 12, no. 2, doi:10.1097/00042737-200012020-00012, pages 203 - 208, XP055408536 [A] 1-9 * the whole document * | |
| SEARCH | - BASS N M, "Review article: the current pharmacological therapies for hepatic encephalopathy.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS FEB 2007 LNKD- PUBMED:17295849, (200702), vol. 25 Suppl 1, ISSN 0269-2813, pages 23 - 31, XP002669397 [A] 1-9 * page 25, column right, paragraph 4th * * page 25, column left, paragraph 3rd * * page 27, column left, paragraph 3rd * * the whole document * | |
| SEARCH | - ZENEROLI MARIA LUISA ET AL, "Management of Hepatic Encephalopathy: Role of Rifaximin", CHEMOTHERAPY, S. KARGER AG, CH, (20050401), vol. 51, no. suppl. 1, doi:10.1159/000081994, ISSN 0009-3157, pages 90 - 95, XP008148562 [A] 1-9 * abstract * * page 93; table 1 * * pages 92,93 * * the whole document * | |
| SEARCH | - STEVEN L. FLAMM, "Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence", THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, UK, (20110501), vol. 4, no. 3, doi:10.1177/1756283X11401774, ISSN 1756-283X, pages 199 - 206, XP055662444 [T] * the whole document * | |
